HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax.

Abstract
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer.
AuthorsSusannah E Motl
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 6 Issue 1 Pg. 104-11 (Feb 2004) ISSN: 1464-8431 [Print] England
PMID15011788 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article)
Chemical References
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Canvaxin
Topics
  • Antigens, Neoplasm (therapeutic use)
  • Cancer Vaccines (therapeutic use)
  • Humans
  • Immunotherapy (methods)
  • Melanoma (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: